Brief: Firebrick Pharma Ltd Says Nasodine Covid-19 Trial Receives Sahpra Approval
31/01/2022 22:52
Feb 1 (Reuters) - Firebrick Pharma Ltd FRE.AX :
* NASODINE COVID-19 TRIAL RECEIVES SAHPRA APPROVAL-FRE.AX
* PLANNED CLINICAL TRIAL OF NASODINE NASAL SPRAY IN COVID-19
PATIENTS IN SOUTH AFRICA RECEIVED APPROVAL TO PROCEED FROM
SAHPRA
Further company coverage: FRE.AX
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement